Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis

Leukemia

Volumn 29, Issue 8, 2015, Pages 1676-1683

  Wild, J ^a   Schmiedel, B J ^a   Maurer, A ^a   Raab, S ^a   Prokop, L ^a   Stevanovic S ^a   Dorfel D ^a   Schneider, P ^b   Salih, H R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CD20 ANTIBODY; FC RECEPTOR; MESSENGER RNA; OBINUTUZUMAB; OFATUMUMAB; RECOMBINANT B CELL ACTIVATING FACTOR; RECOMBINANT CYTOKINE; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B CELL ACTIVATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ARTICLE; CANCER IMMUNOTHERAPY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; PRIORITY JOURNAL; SURFACE PROPERTY; TANDEM MASS SPECTROMETRY; WST-1 ASSAY; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; B LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MASS SPECTROMETRY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PEPTIDE FRAGMENTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 84938999650     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.50     Document Type: Article

References (47)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-49.
2. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-339.
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157.
4. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010; 70: 1445-1476.
5. Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM. Resistance of chronic lymphocytic-leukemia cells to interferon-alpha generated lymphokine activated killer-cells. Leukemia Lymphoma 1992; 7: 473-480.
6. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematologica 1996; 96: 16-23.
7. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63: 305-309.
8. Kay NE, Zarling J. Restoration of impaired natural-killer cell-activity of B-chronic lymphocytic-leukemia patients by recombinant interleukin-2. Am J Hematol 1987; 24: 161-167.
9. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22: 998-1006.
10. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-2073.
11. Platsoucas CD, Fernandes G, Gupta SL, Kempin S, Clarkson B, Good RA et al. Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon. J Immunol 1980; 125: 1216-1223.
12. Spitz DL, Zuckerfranklin D, Nabi ZF. Unmasking of cryptic natural-killer (Nk) cell recognition sites on chronic lymphocytic-leukemia lymphocytes. Am J Hematol 1988; 28: 155-161.
13. Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32: 632-646.
14. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981; 27: 321-327.
15. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010; 116: 3705-3714.
16. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491-502.
17. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-246.
18. Espinosa C, Cervera R. Belimumab, a Blys-specific inhibitor for the treatment of systemic lupus erythematosus. Drugs Today 2010; 46: 891-899.
19. Kamal A. The efficacy of novel B cell biologics as the future of SLE treatment: A review. Autoimmun Rev 2014; 13: 1094-1101.
20. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007; 109: 703-710.
21. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172: 3268-3279.
22. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679-688.
23. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973-2979.
24. Parameswaran R, Muschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 2010; 70: 4346-4356.
25. Maia S, Pelletier M, Ding JX, Hsu YM, Sallan SE, Rao SP et al. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. Plos One 2011; 6: e20787.
26. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106: 376-383.
27. Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, Holler N et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-1756.
28. Schmiedel BJ, Arelin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacyti-dine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128: 2911-2922.
29. Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, Rittig K et al. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol 2012; 42: 737-748.
30. Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009; 69: 1037-1045.
31. Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 2015; 29: 647-659.
32. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T. Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. Cytokine 2008; 44: 44-48.
33. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO R 2001; 2: 945-951.
34. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013; 190: 231-239.
35. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T et al. Preclinical activity of the type II CD20 antibody GA101 (Obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12: 2031-2042.
36. Kuster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat Rev Mol Cell Biol 2005; 6: 577-583.
37. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189: 1360-1371.
38. Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013; 121: 3658-3665.
39. Buechele C, Baessler T, Wirths S, Schmohl JU, Schmiedel BJ, Salih HR. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 2011; 26: 991-1000.
40. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297-302.
41. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002; 196: 1335-1346.
42. Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H et al. Expression of human GITRL on myeloid dendritic cells enhances their immu-nostimulatory function but does not abrogate the suppressive effect of CD4 +CD25+ regulatory T cells. J Leukoc Biol 2007; 82: 93-105.
43. Liu B, Li Z, Mahesh SP, Pantanelli S, Hwang FS, Siu WO et al. GITR negatively regulates activation of primary human NK cells by blocking proliferative signals and increasing NK cell apoptosis. J Biol Chem 2008; 283: 8202-8210.
44. Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Wacker A et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010; 115: 3058-3069.
45. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640-5649.
46. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
47. De Vita S, Quartuccio L, Salvin S, Picco L, Scott CA, Rupolo M et al. Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol 2014; 32: 490-494.